FDA Grants Fast Track Designation to Nektar Therapeutics' Rezpegaldesleukin for Severe Alopecia Areata Treatment

Reuters
29 Jul
FDA Grants <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation to Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' Rezpegaldesleukin for Severe Alopecia Areata Treatment

Nektar Therapeutics announced on July 29, 2025, that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for their investigational biologic therapy, rezpegaldesleukin, aimed at treating severe-to-very severe alopecia areata in adults and children over 12 years old who weigh at least 40 kilograms. Rezpegaldesleukin targets the interleukin-2 receptor complex to promote the proliferation of regulatory T cells, addressing a significant unmet medical need in this chronic, immune-mediated inflammatory disease. This designation allows for more frequent interactions with the FDA and eligibility for accelerated review processes, with Nektar Therapeutics on schedule to release topline data from their Phase 2b study in December.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF39292) on July 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10